Compare AZIO & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZIO | TXMD |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 24.4M |
| IPO Year | 2014 | 2012 |
| Metric | AZIO | TXMD |
|---|---|---|
| Price | $1.19 | $2.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 694.6K | 31.8K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.02 |
| Revenue | ★ $5,939,008.00 | $1,761,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $111.74 |
| Revenue Growth | ★ 217.58 | 35.25 |
| 52 Week Low | $1.08 | $0.99 |
| 52 Week High | $1.84 | $2.95 |
| Indicator | AZIO | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 35.73 | 61.88 |
| Support Level | $1.08 | $2.10 |
| Resistance Level | $1.44 | $2.31 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 20.79 | 73.38 |
Azio AI Holdings Inc is a technology infrastructure company focused on developing, owning, and operating artificial intelligence data centers, enterprise GPU compute infrastructure, digital power solutions, and digital asset mining operations. The company operates an integrated AI infrastructure business encompassing AI data center development, the sale and distribution of enterprise GPU systems and server infrastructure, high-performance computing solutions, power hosting, and strategic technology investments, serving enterprise and institutional customers across domestic and international markets.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.